425: Avalon Secures Hong Kong CAR-T/NK Patent

Avalon GloboCare Corp. announced the issuance of a new 20-year patent in Hong Kong for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology, enhancing its global intellectual property portfolio.

Summary

• Avalon GloboCare Corp. announced the issuance of a new standard patent by the Hong Kong Intellectual Property Department (HKIPD) for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology.
• The patent, HK40074322, is based on a Chinese patent (ZL202080015205.0) and provides 20 years of protection, effective February 21, 2020, through 2040.
• The technology, co-developed and co-owned with Arbele Limited, features a Bispecific Anti-CD19xCD22 CAR Design to reduce tumor escape and Localized Cytokine Induction to activate immune responses at tumor sites.
• The company also noted the ongoing proposed merger with YOOV Group Holding Limited, for which a Registration Statement on Form S-4 has been filed but is not yet effective.

Sentiment

Score: 8

Explanation: The patent issuance is a strong positive development, indicating innovation and strengthening the company's competitive position in a high-growth therapeutic area. While the filing also mentions a merger, the primary positive news is the patent.

Positives

• Securing a 20-year patent in Hong Kong for advanced CAR-T and CAR-NK cell technology significantly strengthens the company's global intellectual property portfolio.
• The patented technology's Bispecific Anti-CD19xCD22 CAR Design is expected to reduce the risk of tumor escape, a common challenge in hematologic malignancies.
• Localized Cytokine Induction is intended to improve CAR cell proliferation, cytotoxicity, and persistence, while also attempting to stimulate the patient's own immune system.
• The patent complements existing protections in the United States and other jurisdictions under the Patent Cooperation Treaty (PCT).

Risks

• Actual results may differ materially from forward-looking statements due to various important factors disclosed in SEC filings, including general industry and market conditions, economic conditions, and governmental and public policy changes.
• The Bispecific Anti-CD19xCD22 CAR Design is 'expected to reduce' tumor escape, implying it is not a guaranteed elimination of risk.
• Localized Cytokine Induction is 'intended to activate' and 'attempting to stimulate,' indicating potential for less than full efficacy.

Future Outlook

The company aims to continue advancing its intellectual property portfolio and developing additional diagnostic uses for its breathalyzer technology. The patented CAR-T and CAR-NK cell technology is expected to enhance manufacturing, expansion, survival, and therapeutic efficacy of CAR cells, potentially reducing tumor escape and stimulating patient immune responses. The proposed merger with YOOV Group Holding Limited is ongoing, with relevant SEC filings made.

Management Comments

• Securing this patent in Hong Kong marks an important expansion of our global intellectual property portfolio and reinforces our competitive positioning in the rapidly advancing field of cell-based immunotherapy.
• With 20 years of patent protection for our CAR-T and CAR-NK cell technology now secured in Hong Kong through 2040, this achievement represents a strategic step in strengthening our intellectual property portfolio.

Industry Context

The patent issuance positions Avalon GloboCare within the rapidly advancing field of cell-based immunotherapy, specifically CAR-T and CAR-NK cell therapies, which are key areas of innovation in oncology. The focus on bispecific targeting (CD19xCD22) and localized cytokine induction addresses known challenges in current CAR therapies, such as antigen loss and persistence, aligning with broader industry efforts to improve efficacy and safety of these treatments.

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to strengthened intellectual property and competitive positioning in a high-growth market. The proposed merger with YOOV Group Holding Limited will require shareholder approval.
• Patients: Potential for more effective and safer CAR-T and CAR-NK cell therapies for hematologic malignancies.
• Strategic Partner (Arbele Limited): Continued collaboration and shared benefits from the co-owned patent.

Next Steps

• Development of additional diagnostic uses for the breathalyzer technology.
• Advancing the intellectual property portfolio through existing patent applications.
• Completion of the proposed merger with YOOV Group Holding Limited, including the SEC declaring the Registration Statement on Form S-4 effective.
• Stockholders are urged to read the definitive proxy statement/prospectus when it becomes available before making any voting or investment decision regarding the proposed merger.

Key Dates

Recommendation

The patent issuance is a significant positive, strengthening Avalon's intellectual property and competitive position in the promising cell therapy space. This development supports the company's long-term growth prospects. However, the company also operates in precision diagnostic consumer products and commercial real estate, indicating a diversified but potentially less focused strategy. The ongoing merger with YOOV Group Holding Limited introduces an element of uncertainty until its completion. Given the positive patent news but also the broader business diversification and pending merger, a 'hold' recommendation is appropriate for investors to monitor the integration of the new technology into commercialization plans and the outcome of the merger.

Keywords

CAR-T, CAR-NK, Cell Therapy, Immunotherapy, Patent, Intellectual Property, Biotechnology, Oncology, Hematologic Malignancies, Hong Kong, NASDAQ: ALBT, Avalon GloboCare